BGNE241115C100000
- 43.90
- 0.000.00%
BeiGene Newsroom
bocom intl: raised beigene (06160) target price to 159 Hong Kong dollars. Q3 product sales and operation continue to improve.
[Brokerage Focus] Bocom Intl raises the target price of Beigene (06160) and points out that product sales and operation continue to improve in Q3 2024.
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
BeiGene's Strong Financial Performance and Growth Potential Justifies Buy Rating
Research reports Focus丨Tianfeng: Beigene Q3 adjusted operating profit reached $65.6 million, maintaining a "buy" rating
[Brokerage Focus] Guoyuan International cuts Beigene (06160) target price to HK$153, pointing to 3Q24 performance slightly below expectations.
BEIGENE LTD(6160.HK):3Q24 REVENUE MILESTONE OF US$1BN+ WITH ROBUST PIPELINE PROGRESS DESPITE SIGNS OF MARKET MODERATION
BeiGene (688235): Continuous profit core under NON-GAAP caliber, excellent clinical data in the research pipeline
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Analyst Ratings
BeiGene (6160.HK): 3Q24 product sales and operations continue to improve, and the catalyst is about to be intensively implemented to raise target prices
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (688235): Product revenue continued to grow high in the third quarter, and net cash inflows from operating activities were corrected
BeiGene (6160.HK): Continued high revenue growth and deepening global layout
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Credit Suisse: Raises the target price of Beigene to HK$156.8, reiterates 'outperform' rating.
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $260
BeiGene's Strong Performance and Promising Pipeline Drive Buy Rating
BeiGene (688235): Overseas zebutinib revenue reached a new high
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288